Drug firm Unichem Laboratories on Friday said it has not received any observations from the US health regulator following completion of inspection of the company’s facility in Ghaziabad, Uttar Pradesh. The facility was inspected by the United States Food and Drug Administration from April 16 to April 20, Unichem Laboratories said, and added that this inspection also covered one of the ‘first to file’ molecules. Shares of the company may see buying interest on this announcement.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.